Federated Hermes Inc. Lowers Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Federated Hermes Inc. reduced its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 22.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,081 shares of the specialty pharmaceutical company’s stock after selling 14,585 shares during the quarter. Federated Hermes Inc. owned 0.09% of Supernus Pharmaceuticals worth $1,449,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Polar Capital Holdings Plc grew its holdings in shares of Supernus Pharmaceuticals by 10.0% in the third quarter. Polar Capital Holdings Plc now owns 1,654,470 shares of the specialty pharmaceutical company’s stock worth $45,614,000 after purchasing an additional 150,000 shares during the last quarter. Congress Asset Management Co. MA increased its stake in shares of Supernus Pharmaceuticals by 19.1% during the third quarter. Congress Asset Management Co. MA now owns 917,164 shares of the specialty pharmaceutical company’s stock valued at $25,286,000 after buying an additional 147,105 shares during the period. Loomis Sayles & Co. L P grew its stake in Supernus Pharmaceuticals by 8.6% in the third quarter. Loomis Sayles & Co. L P now owns 1,730,269 shares of the specialty pharmaceutical company’s stock worth $47,703,000 after purchasing an additional 136,964 shares during the period. Armistice Capital LLC raised its holdings in Supernus Pharmaceuticals by 1.1% in the third quarter. Armistice Capital LLC now owns 5,092,000 shares of the specialty pharmaceutical company’s stock worth $140,386,000 after purchasing an additional 56,000 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in Supernus Pharmaceuticals by 8.0% during the third quarter. Victory Capital Management Inc. now owns 711,169 shares of the specialty pharmaceutical company’s stock valued at $19,607,000 after buying an additional 52,468 shares during the period.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 14,491 shares of the stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $35.31, for a total transaction of $511,677.21. Following the sale, the vice president now directly owns 8,570 shares of the company’s stock, valued at approximately $302,606.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Padmanabh P. Bhatt sold 14,491 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $35.31, for a total value of $511,677.21. Following the transaction, the vice president now directly owns 8,570 shares of the company’s stock, valued at approximately $302,606.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 3,884 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $32.99, for a total value of $128,133.16. Following the sale, the vice president now owns 8,570 shares in the company, valued at $282,724.30. The disclosure for this sale can be found here. Insiders sold a total of 35,739 shares of company stock valued at $1,227,433 in the last quarter. 8.76% of the stock is owned by insiders.

Supernus Pharmaceuticals Trading Up 1.8 %

SUPN stock opened at $30.60 on Tuesday. The firm has a 50 day moving average price of $31.56 and a 200-day moving average price of $28.67. Supernus Pharmaceuticals, Inc. has a 52-week low of $21.99 and a 52-week high of $38.09.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.39). Supernus Pharmaceuticals had a net margin of 0.22% and a return on equity of 0.14%. The company had revenue of $164.30 million for the quarter, compared to the consensus estimate of $155.03 million. During the same period last year, the business earned $0.43 EPS. The firm’s quarterly revenue was down 1.8% on a year-over-year basis. Research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Piper Sandler reduced their target price on shares of Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 28th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.